The Smorodintsev Research Institute of Influenza, a federal institution under the Russian Ministry of Health, is in the process of creating a long-lasting vaccine against the influenza A virus. This innovative vaccine aims to provide protection against infection for several years. The director of the research institute, Dmitry Lioznov, announced at a conference in Novosibirsk that the drug is now in the preclinical trial phase.
He explains that the development is still in its early stages and has not yet entered clinical trials. The vaccine is designed to be administered just once every few years, offering long-lasting protection. The drug is being developed taking into account the current circulating strains of the virus.
